|
|
WI-38
|
|
|
L Hayflick
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
fibroblast
|
|
|
Organ: lung
Disease: normal
Cell Type: fibroblast
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
testing [92346] [92389]
transfection host (Nucleofection technology from Lonza
Roche FuGENE® Transfection Reagents)
viruscide testing
|
|
|
Vesicular stomatitis, Glasgow (Indiana)
Herpes simplex virus
Pseudorabies virus
Human poliovirus 1
|
|
|
negative
|
|
|
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 11,12
D5S818: 10
D7S820: 9,11
THO1: 8,9.3
TPOX: 8
vWA: 19,20
|
|
|
normal diploid
|
|
|
G6PD, B
|
|
|
3 months gestation fetus
|
|
|
female
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Trypsin and medium should be prewarmed to 37C and the pH should be adjusted to 7.5 before use.
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 to 3 times per week
|
|
|
growth medium, 95%; DMSO, 5%
|
|
|
24 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
|
|
|
21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111
22194: Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25: 585-621, 1961. PubMed: 13905659
22197: Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37: 614-636, 1965. PubMed: 14315085
26220: Hayflick L, et al. Preparation of poliovirus vaccines in a human fetal diploid cell strain. Am. J. Hyg. 75: 240-258, 1962. PubMed: 13905660
26223: . First International Conference on Vaccines against Viral and Rickettsial Diseases of Man. Pan Am. Health Organ. Off. Doc. 147: 581, 1967.
29375: Tomasek JJ, et al. Gelatinase A activation Is regulated by the organization of the polymerized actin cytoskeleton. J. Biol. Chem. 272: 7482-7487, 1997. PubMed: 9054450
32244: Hoppe HC, et al. Identification of phosphatidylinositol mannoside as a mycobacterial adhesin mediating both direct and opsonic binding to nonphagocytic mammalian cells. Infect. Immun. 65: 3896-3905, 1997. PubMed: 9284169
32288: Landers JE, et al. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57: 3562-3568, 1997. PubMed: 9270029
32582: Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591
|
|
|
